Drugs / Sevuparin
Sevuparin
Trials 3 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 11 trial | ||||||
| Phase 1 | NCT03853421 | Feb → May 2019 | — | Modus Therapeutics AB | Completed | No outcome recorded |
| Phase 1/21 trial | ||||||
| Phase 1/2 | NCT01442168 | Sep 2011 → Sep 2013 | Plasmodium falciparum malaria | Modus Therapeutics AB | Terminated | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT02515838 | Jul 2015 → May 2019 | sickle cell disease | Modus Therapeutics AB | Completed | No outcome recorded |
Evidence & citations 5 cited values
Every value below carries the sentence it was read from. 6 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | Sevuparin | ClinicalTrials.gov intervention name — accepted as the source's own label NCT01442168 ↗ |
| Known as | DF-02 | ChEMBL registry synonym — accepted as the source's own label CHEMBL4297825 ↗ |
| Known as | Sevuparin/DF02 | “Sevuparin/DF02 as an Adjunctive Therapy in Subjects Affected With Uncomplicated Falciparum Malaria” NCT01442168 ↗ |
| Modality | Other / unclassified | “novel non-anticoagulant low molecular weight heparinoid” PMID 33894169 ↗ May 2021 |
| Route | Intravenous | “sevuparin was administered via short intravenous infusions” PMID 29244851 ↗ Dec 2017 |